The frontline combination of ibrutinib (Imbruvica) and nab-paclitaxel (Abraxane)/gemcitabine did not show a statistically significant benefit in progression-free or overall survival (OS) versus placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer, according to topline findings of the phase
The full findings of this study will be submitted for presentation at an upcoming medical meeting and/or publication, announced AbbVie, the developer of ibrutinib, in a press release. Read more . . .